DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
- Registration Number
- NCT04845646
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Brief Summary
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of ASC41, a THR beta agonist tables in healthy subjects. The PK, Safety and Tolerability of ASC 41 in Subjects with NAFLD will also be evaluated. Approximately 24 subjects including 16 healthy volunteers (HVs) and 8 subjects with NAFLD will be enrolled. This study consists of 3 cohorts.
- Detailed Description
This multiarm study in HVs and subjects with NAFLD is designed to further characterize the PK, safety and tolerability of ASC41. Part I of the study will assess the effect of itraconazole and phenytoin on the single-dose PK of ASC41 in HVs. Part II of the study will evaluate the PK, safety and tolerability of a single dose of ASC41 in subjects with NAFLD. The pharmacokinetics of ASC41 and its metabolite ASC41-A will be assessed in both parts I and II. The secondary objective of the study is to characterize the safety and tolerability of oral ASC41 in subjects in the U.S. with NAFLD and in HVs. Approximately 24 male and female participants will be enrolled. This study consists of 3 cohorts.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
-
Part I Healthy subjects between 18 to 55 years of age
-
Part II
- Subjects with NAFLD
- Subjects between 18 to 65 years of age
Key Exclusion criteria:
-
Part I
- A history of thyroid disease
- A history of, or current liver disease, or liver injuries
- Platelet count <150,000/mcL
- INR> 1.2
- History of, or current electrocardiogram (ECG) abnormalities, arrhythmias or heart valve diseases judged to be clinically significant by the investigator
-
Part II
- A history of thyroid disease
- Current or history of cirrhosis or decompensated liver disease
- AST or ALT > 5X ULN
- DBIL > ULN
- Acute or chronic liver disease other than NAFLD
- A history of bariatric surgery
- HbA1c >9.5% at screening
- Testosterone or estrogen replacement therapy
- Inducers or inhibitors of CYP3A4, including herbal therapies such as St John's Wort (CYP3A4 Inducer)
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ASC41 + Itraconazole group ASC41 1. ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11. 2. Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16. ASC41 + Itraconazole group Itraconazole 1. ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 11. 2. Itraconazole oral capsule 200 mg po qd (2 capsules given 1x/day or 200 mg/day) on days 6-16. ASC41 + Phenytoin group Phenytoin 1. ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19. 2. Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19. ASC41 + Phenytoin group ASC41 1. ASC41 5 mg po, One 5 mg ASC41 tablet on day 1 and 19. 2. Phenytoin oral capsule 300 mg (100 mg 3 x/day) on days 6-19. ASC41 group ASC41 (1) ASC41 5 mg po. One 5 mg ASC41 tablet on day 1.
- Primary Outcome Measures
Name Time Method Cmax of ASC41 Up to 24 days Evaluate the Peak Plasma Concentration.
AUC of ASC41 Up to 24 days Evaluate the Area under the plasma concentration versus time curve.
- Secondary Outcome Measures
Name Time Method t1/2 of ASC41 Up to 24 days Evaluate the Terminal-Phase Half-Life.
CL/F of ASC41 Up to 24 days Evaluate the Apparent Systemic Clearance.
Vd/F of ASC41 Up to 24 days Evaluate the Apparent Volume of Distribution.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Up to 24 days Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation and/or dose reductions, and AE of special interest, from baseline up to 24 days.
Trial Locations
- Locations (1)
ICON early Phase Services LLC
🇺🇸San Antonio, Texas, United States